AstraZeneca Can Absorb Impact of US Drug-Pricing Deal, CFO Says

AstraZeneca Plc can absorb the financial impact of its recent deal with the US next year as demand for innovative medicines makes up for reduced prices in the world’s biggest pharma market, according to its chief financial officer.

The agreement, clinched in October, will see the UK drugmaker reduce prices for some of its medicines and launch products at the same cost in the US as in other wealthy countries.